All patients (N=48) | Evolocumab (N=33) | Alirocumab 150 mg (N=9) | Alirocumab 75 mg (N=6) | |
Influenza-like symptoms | 12 (25) | 10 (30)* | 1 (11) | 1 (17) |
Fatigue/lethargy | 10 (21) | 5 (15) | 5 (56) | 0 (0) |
Nausea | 6 (13) | 4 (12) | 2 (22) | 0 (0) |
Musculoskeletal pain | 4 (8) | 1 (3) | 3 (33)† | 0 (0) |
Injection-site reaction | 2 (4) | 2 (6) | 0 (0) | 0 (0) |
All data are n (%). All symptoms were transient and were reported within the first 3 months of initiation.
*Three patients discontinued due to influenza-like symptoms.
†Two patients discontinued due to musculoskeletal pain.
PCSK9is, proprotein convertase subtilisin/kexin type 9 inhibitors.